WHO Grade 3 Glioma — Trials

WHO Grade 3 Glioma — Trials · CancerIndex

Clinical trials

Registered studies

258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 32
Ph III recruiting: 2
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01096368	Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma	completed	Phase 3	479	Children's Oncology GroupNETWORK	4	Apr 30, 2026	clinicaltrials
NCT01236560	Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma	completed	Phase 2 / Phase 3	101	National Cancer Institute (NCI)NIH	2